Mr. Vijay Karwal
- Executive Director & Chief Financial Officer, AffaMed Therapeutics
Vijay Karwal is an Executive Director and Chief Financial Officer of AffaMed Therapeutics, based in Hong Kong. He brings over 27 years of global financial management and advisory experience in the healthcare industry with extensive background in business development, M&A and capital raising gained in roles in industry and as a senior investment banker. He is also an Operating Partner at leading Asian healthcare investor CBC Group and serves as an Independent Director of Mega Lifesciences PCL, one of the largest pharmaceutical groups in Southeast Asia, exchange listed and headquartered in Bangkok, Thailand.
Vijay joined AffaMed from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the international provider of kidney care services. Vijay previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, as Head of Healthcare Banking in North America at ABN AMRO, and as a senior member of ABN AMRO Rothschild – the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector, gaining extensive global experience across postings in London, Chicago, New York, Singapore and Hong Kong.
A native of the Netherlands, Mr. Karwal was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charterholder.